ASX Announcement

Race Executes Contracts to Commence Observational Cardioprotection Breast Cancer Trial

- **Contract Research Organisations Resolutum Global, Beyond Drug Development, and NSW Regional Biospecimen & Research Services have been appointed to support the Zantrene breast cancer cardioprotection clinical program**
- **Clinical trial institutional governance submission is expected soon and will enable enrolment of the first study patient**
- **This observation trial will place a spotlight on the irreversible damage to the heart that can be induced by AC chemotherapy and is the first step in advancing the Zantrene cardioprotection opportunity in the clinic.**

---

13 March 2023 – Race Oncology Limited ("Race") is pleased to announce it has appointed the Contract Research Organisations *Resolutum Global*, *Beyond Drug Development*, and *NSW Regional Biospecimen & Research Services*, to support the observational stage of a Phase 1/2b clinical trial of Zantrene® (bisantrene) in breast cancer patients treated with doxorubicin and cyclophosphamide and who have two or more cardiovascular risk factors.

This observational study will recruit and monitor up to 50 patients being treated for breast cancer using the standard of care (SoC) regimen of doxorubicin (Adriamycin®) and cyclophosphamide – referred to as "AC chemotherapy". The aim of this study is to identify the rate and level of heart damage caused by AC chemotherapy using modern, advanced cardiac imaging and biochemical methods. In addition, the anti-cancer efficacy of AC chemotherapy will be monitored using a liquid biopsy (DNA) approach.

The data from this study will inform the design of a subsequent Phase 1/2b interventional trial that may help patients to avoid the permanent heart damage that can be caused by AC chemotherapy, while improving anti-cancer outcomes. These human trials are fully funded from capital raised in December 2021 (ASX Announcement: 21 December 2021).

Details of the observational trial design and purposes have been previously described (ASX Announcement: 9 December 2022) and human ethics approval was recently granted (ASX Announcement: 1February 2023).

Under the terms of the contracts signed, Race will pay *Resolutum Global* $422,389.59 for data management and biostatistics services; *Beyond Drug Development* $658,296.75 for clinical site management and monitoring, safety management reporting, and clinical study report development services; and *NSW Regional Biospecimen & Research Services* $206,928.50 for patient sample kit production, processing and sample storage services.

Race CEO Mr Damian Clarke-Bruce commented, *"This study launches our clinical journey of advancing Zantrene to protect vulnerable patients from the serious and irreversible heart*

damage that can result from current breast cancer treatments. After spending a week with Cardio-Oncologists at ACC23 it is evident that chemotherapy induced heart damage remains a significant concern with limited therapeutic options. Improving cancer patients' quality of life has become an increasing goal for pharmaceutical companies and Zantrene has the potential to fill this unmet clinical need."

Race CSO Dr Daniel Tillett commented, *"I am very pleased Race will be working with Resolutum Global, Beyond Drug Development, and NSW Regional Biospecimen & Research Services to advance our cardioprotection opportunity for Zantrene in the clinic. Gaining high quality observational data to help design our interventional Phase 1/2b trial of Zantrene in breast cancer patients will be critical to the success of this program."*

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target cancer.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in multiple clinical trials in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Zantrene. Learn more at www.raceoncology.com

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub https://announcements.raceoncology.com

Release authorised by:

Damian Clarke-Bruce, CEO/MD on behalf of the Race Board of Directors

damian.clarke-bruce@raceoncology.com

Media contact:

Jane Lowe

+61 411 117 774

jane.lowe@irdepartment.com.au